Longevity medicine — the systematic clinical practice of extending healthy lifespan (healthspan) through measurable biological intervention — has emerged from fringe biohacking circles into mainstream clinical practice, with dedicated longevity clinics now operating in every major city and health systems like Mayo Clinic and Cleveland Clinic launching dedicated longevity programs. The scientific foundation has grown substantially: mechanistic understanding of aging hallmarks (Hallmarks of Aging, López-Otín, 2023 updated 12-hallmark framework), validated biomarkers of biological age, and emerging interventional evidence provides a framework for rational clinical practice. Our diagnostic equipment section supports laboratory monitoring for longevity-focused clinical programs.
Biological Age Biomarkers
Chronological age is an imperfect proxy for biological aging. Validated biological age measures: DNA methylation clocks (Horvath, PhenoAge, GrimAge) analyze CpG methylation patterns across the genome to estimate biological age — GrimAge is most predictive of all-cause mortality. Composite phenotypic age scores (PhenoAge) incorporate chronological age plus albumin, creatinine, glucose, CRP, lymphocyte %, MCV, RDW, alkaline phosphatase, and white blood cell count — producible from standard labs and predictive of mortality beyond chronological age. Telomere length: measures telomeric repeats as a proxy for replicative cellular aging; high inter-individual variability limits clinical utility as a standalone metric. Our lab supplies and diagnostic sections support the clinical laboratory monitoring central to longevity programs.
Evidence-Supported Longevity Interventions
Lifestyle: exercise (particularly VO2 max and muscle mass, with 5-year higher VO2 max decile associated with 45% lower all-cause mortality in the JAMA study), sleep optimization, caloric restriction equivalents (time-restricted eating — 16:8 intermittent fasting), stress reduction, and social connection all have robust epidemiological association with longevity. Pharmacological: metformin (TAME trial — Trial to Assess Metformin in Aging — ongoing, testing metformin's healthspan extension based on observational data showing lower age-related disease in diabetic patients on metformin vs other antidiabetics); rapamycin/mTOR inhibition (the only drug class consistently extending lifespan across multiple model organisms — ITP program, human clinical trials emerging); senolytic drugs (dasatinib + quercetin — FDA clinical trials for multiple age-related conditions underway). NAD+ precursors (NMN, NR): significant industry investment and preclinical evidence; human trial evidence for meaningful aging endpoints remains limited despite strong mechanistic rationale. Our nutrition catalog includes clinical-grade nutritional supplements used in longevity protocols.
